- Open Access
Homeostatic mechanisms in dopamine synthesis and release: a mathematical model
© Best et al; licensee BioMed Central Ltd. 2009
- Received: 23 April 2009
- Accepted: 10 September 2009
- Published: 10 September 2009
Dopamine is a catecholamine that is used as a neurotransmitter both in the periphery and in the central nervous system. Dysfunction in various dopaminergic systems is known to be associated with various disorders, including schizophrenia, Parkinson's disease, and Tourette's syndrome. Furthermore, microdialysis studies have shown that addictive drugs increase extracellular dopamine and brain imaging has shown a correlation between euphoria and psycho-stimulant-induced increases in extracellular dopamine . These consequences of dopamine dysfunction indicate the importance of maintaining dopamine functionality through homeostatic mechanisms that have been attributed to the delicate balance between synthesis, storage, release, metabolism, and reuptake.
We construct a mathematical model of dopamine synthesis, release, and reuptake and use it to study homeostasis in single dopaminergic neuron terminals. We investigate the substrate inhibition of tyrosine hydroxylase by tyrosine, the consequences of the rapid uptake of extracellular dopamine by the dopamine transporters, and the effects of the autoreceoptors on dopaminergic function. The main focus is to understand the regulation and control of synthesis and release and to explicate and interpret experimental findings.
We show that the substrate inhibition of tyrosine hydroxylase by tyrosine stabilizes cytosolic and vesicular dopamine against changes in tyrosine availability due to meals. We find that the autoreceptors dampen the fluctuations in extracellular dopamine caused by changes in tyrosine hydroxylase expression and changes in the rate of firing. We show that short bursts of action potentials create significant dopamine signals against the background of tonic firing. We explain the observed time courses of extracellular dopamine responses to stimulation in wild type mice and mice that have genetically altered dopamine transporter densities and the observed half-lives of extracellular dopamine under various treatment protocols.
Dopaminergic systems must respond robustly to important biological signals such as bursts, while at the same time maintaining homeostasis in the face of normal biological fluctuations in inputs, expression levels, and firing rates. This is accomplished through the cooperative effect of many different homeostatic mechanisms including special properties of tyrosine hydroxylase, the dopamine transporters, and the dopamine autoreceptors.
- Tyrosine Hydroxylase
- Firing Rate
- Substrate Inhibition
- Extracellular Dopamine
Dopamine is a catecholamine that is used as a neurotransmitter both in the periphery and in the central nervous system (CNS)[2–4]. Important nuclei that contain dopaminergic neurons include the substantia nigra pars compacta and the ventral tegmental area . These nuclei send projections to the neostriatum, the limbic cortex, and other limbic structures .
Dopamine is known to play an important role in many brain functions. Dopamine affects the sleep-wake cycle , it is critical for goal-directed behaviors  and reward-learning , and modulates the control of movement via the basal ganglia [9, 10]. Cognitive processing, such as executive function and other pre-frontal cortex activities, are known to involve dopamine . Finally, dopamine contributes to synaptic plasticity in brain regions such as the striatum and the pre-frontal cortex [12–14].
Dysfunction in various dopaminergic systems is known to be associated with various disorders. Reduced dopamine in the pre-frontal cortex and disinhibited striatal dopamine release is seen in schizophrenic patients . Loss of dopamine in the striatum is a cause of the loss of motor control seen in Parkinson's patients . Studies have indicated that there is abnormal regulation of dopamine release and reuptake in Tourette's syndrome . Dopamine appears to be essential in mediating sexual responses . Furthermore, microdialysis studies have shown that addictive drugs increase extracellular dopamine and brain imaging has shown a correlation between euphoria and psycho-stimulant-induced increases in extracellular dopamine . These consequences of dopamine dysfunction indicate the importance of maintaining dopamine functionality through homeostatic mechanisms that have been attributed to the delicate balance between synthesis, storage, release, metabolism, and reuptake [19, 20]. It is likely that these mechanisms exist both at the level of cell populations [21, 22] and at the level of individual neurons.
In this paper we construct a mathematical model of dopamine synthesis, release, and reuptake and use it to study homeostasis in single dopaminergic neuron terminals. It is known that the enzyme tyrosine hydroxylase (TH), the rate limiting enzyme in dopamine synthesis, has the unusual property of being inhibited by its own substrate, tyrosine . Cytosolic dopamine concentrations are normally quite low because most dopamine resides in vesicles from which it is released on the arrival of action potentials. After release, dopamine is rapidly taken up by dopamine transporters (DATs) on the terminal and it is thought that the DATs play an important role in extracellular dopamine homeostasis [24, 25]. Autoreceptors are found on most parts of dopaminergic neurons, in particular the neuron terminal. It was first proposed in the 1970's [26, 27] that the binding of dopamine to presynaptic autoreceptors affects TH and therefore the synthesis of dopamine. It is now known that increased extracellular dopamine can inhibit TH by at least 50% [28, 29] and the data in , , and  suggest that when extracellular dopamine drops, synthesis can be increased by a factor of 4 to 5. The purpose of our modeling is to tease apart the contributions of these various mechanisms to the homeostasis of dopamine synthesis, release, and reuptake.
There have been a number of other models of dopamine dynamics. Ours is closest in spirit to the quite comprehensive model by Justice  based on experimental work by Justice, Michael and others [34–36]. They did not consider fluctuations in blood tyrosine or intracellular tyrosine nor did they consider the effects of autoreceptors. The model by Porenta and Riederer  is less detailed but does include the effects of autoreceptors. Tretter and Eberie  have a very simple model of behavior at the synapse. Nicholson  studied the difficult mathematical questions involved in diffusion and reuptake of dopamine in extracellular spaces with realistic irregular geometry. Qi et al. [40, 41] use a general modeling framework in which the rates of change of all variables are written as sums of powers of the other variables and then coefficients and exponents are determined by fitting data. Kaushik et al.  focus on the regulation of TH by phosphorylation, iron, and α-synuclein. Fuente-Fernandez et al.  created a probabilistic model of synthesis and release to see if stochastic variation could cause the motor fluctuations in Parkinson's disease. Wightman and co-workers use models of release into and reuptake from the extracellular space to infer properties of the DATs and to interpret their data on the time courses of extracellular dopamine [44–47]. They added diffusion in the extracellular space in  and used the model and their experiments to show that the concentration of DA is quite uniform in the extracellular space during tonic firing but not during burst firing.
We use the mathematical model as a platform on which to investigate the system effects of variations in quantities such as enzyme expression levels, tyrosine inputs, firing rate changes, and concentrations of dopamine transporters. We find that dopaminergic function is under tight regulatory control so that the system can respond strongly to significant biological signals such as bursts, but responds only moderately to the normal noisy fluctuations in the component parts of the system.
the tyrosine pool
Kinetic Parameters (μ M, μ M/hr,/hr).
aromatic amino acid decarboxylase
K bh 2
K bh 4
vesicular monoamine transporter
K bh 4
K i (cda)
K i (substrate inhibition)
K i (autoreceptors)
neutral amino acid transporter
tyr ↔ tyrpool
catabolism and diffusion
for unidirectional, one substrate, unidirectional, two substrates, and bidirectional, two substrates, two products, respectively.
Tyrosine and the tyrosine pool
If btyr has its average value of 97 μ M, then VTYRin = 244 μ M/hr, which corresponds almost exactly to the 4 μ M/min reported in  for the import of tyrosine into the brain.
We choose the rate constants k1 = 6 μ M/hr and k-1 = 0.6 μ M/hr so that tyrpool is approximately 10 time larger than tyr. As we will see below, with this choice, about 10% of the imported tyrosine goes to dopamine synthesis and the steady state tyrosine concentration is 126 μ M in the model, well within the normal range of 100-150 μ M . The importance of tyrpool is that, without it, all imported tyrosine would have to go to dopamine in the model. Not only would that be incorrect physiologically, but dopamine synthesis would be extremely sensitive to tyrosine import, which it is not [57, 58, 56].
The second term (on the right) requires more discussion. It was first proposed in the 1970's [26, 27] that the binding of dopamine to presynaptic autoreceptors affects TH and therefore the synthesis of dopamine. Although the details of the mechanisms are not certain, research since that time has demonstrated clearly that the autoreceptors modulate the activity of TH as well as the neuronal firing rate and the release of dopamine[29, 28, 61–63, 30, 64, 31]. All three effects are consistent: higher eda means more stimulation of the autoreceptors and this decreases the activity of TH [29, 63], lowers firing rate [61, 62], and inhibits release [28, 29]. The evidence in these papers suggests that dopamine agonists can inhibit TH by at least 50% [28, 29]. The more difficult question is how much synthesis is increased if the normal inhibition by the autoreceptors is released? In  only a 40% increase was found, but the data in  and  suggest that synthesis can be increased by a factor of 4 to 5. This is consistent with the original data in , Table 1. The third factor in the formula for VTH(tyr, bh 4, cda, eda) has the following properties: at the normal steady state it equals one; as eda gets large it approaches 0.5; as eda gets smaller and smaller it approaches 5. The exponent 4 was chosen to approximate the data in , figure 2. Note that, in this first model, we are not including explicitly the effects of the autoreceptors on firing rate and dopamine release.
Storage, release, and reuptake of dopamine
After dopamine is synthesized it is packaged into vesicles by the vesicular monoamine transporter, MAT. We take the K m of the transporter in the literature range (see Table 2) and choose the V max so that the concentration of cytosolic dopamine is in the range 2-3 μ M under normal circumstances. The experiments in  and the calculations in  suggest strongly that there is transport from the vesicles back into the cytosol, either dependent or independent of the MAT. We assume this transport is linear with rate constant, k out , chosen so that the vast majority (i.e., 97%) of the cellular dopamine is in the vesicular compartment. The vesicles take up a significant fraction of the volume terminal, perhaps 1/4 to 1/3 (reference). For simplicity we are assuming that the vesicular compartment is the same size as the non-vesicular cytosolic compartment. This assumption is unimportant since we take the cytosol to be well-mixed and we are not investigating vesicle creation, movement toward the synapic cleft, and recyling where geometry and volume considerations would be crucial.
Vesicular dopamine, vda, is put into the synaptic cleft, where it becomes eda, by the term fire(t)(vda) in the differential equations for vda and eda (see above). fire is a function of time in some of our in silico experiments, for example in Results G where we investigate individual spikes. However, for most of our experiments fire = 1 μ M/hr, which means that vesicular dopamine is released at a constant rate such that the entire pool turns over once per hour. This is consistent with a variety of experimental results on turnover and we will see in Results C that this choice gives decay curves after α-methyl-p-tyrosine (α-MT) inhibition of TH that match well the findings of Caron and co-workers [24, 25].
Extracellular dopamine has three fates. It is pumped back into the cytosol by the DATs; it is catabolized; it is removed from the system. The parameters for the DATs are taken from the literature. The other two fates are discussed next.
Metabolism and removal of dopamine
Cytosolic dopamine is catabolized by monoamine oxidase (MAO) and aldehyde dehydrogenase to dihydrophenylacetic acid (dopac), which is exported from the neuron and methylated by catecholamine methyl transferase (COMT) to homovanillic acid (hva). In this simple model we are not investigating the details of catabolism, only how cda is removed from the system. Since the cytosolic dopamine concentration is low (2-3 μ M) and the K m for MAO is high (210-230 μ M, ), the removal of cda is basically a linear process that we model by the first order term (cda). We choose the rate constant = 10/hr so that the rate of cytosolic catabolism is somewhat less than the synthesis rate of cda at steady state. Extracellular dopamine is also catabolized, first by COMT and then by MAO. In this case, we use a Michaelis-Menten formula for this process because the K m of dopamine for COMT is low enough (approximately 3 μ M, ) that the process saturates in some of our in silico experiments in which large amounts of DA are dumped into the extracellular space. The half-life of hva is the brain is approximately hr [69, 70], which determines = 3.45/hr for the removal of hva from the system.
In our model the extracellular space is a single compartment. One should think of it as the part of the entire extracellular space corresponding to this particular synapse. Of course, if we had many model synapses, the eda from one will diffuse into the extracellular compartment of another (volume transmission). We are assuming for simplicity that the extracellular space is well-mixed, that is, we are ignoring diffusion gradients between different parts of the extracellular space. In fact, Venton et al.  have shown using a combination of experiments and modeling that the extracellular space is well-mixed during tonic firing but that substantial gradients exists between "hot spots" of release and reuptake and the rest of the extracellular space during and just after episodes of burst firing. In addition, when SNc projections die, as in Parkinson's disease or in denervation experiments, the terminals will be further apart making it certain that diffusion gradients will play an important role (see the Discussion). The term k rem (eda) in the differential equation for eda represents removal of eda through uptake by glial cells, uptake by the blood, and diffusion out of the striatum. After some experimentation we chose k rem = 400/hr because it gave good fits to the experimental data in  discussed in Results B and the experimental data in [24, 25] discussed in Results D.
In all cases, steady states or curves showing the variables as functions of time were computed using the stiff ODE solver in MATLAB.
Steady state concentrations and fluxes
Figure 1 shows the concentrations and velocities at steady state in our model. Only about 10% of the cellular tyrosine input goes to dopamine synthesis with the remainder going to the tyrosine pool (80%) or being catabolized (10%) as seen experimentally [53–55]. Cellular tyrosine itself has a steady state concentration of 126 μ M in the model consistent with a large number of experimental observations [58, 56, 4].
It is known that the cytosolic concentration of dopamine is quite low and the concentration of l-dopa is extremely low . In the model, at steady state, cda = 2.65 μ M and the concentration of l-dopa is 0.36 μ M, consistent with these observations. It is instructive to look at the flux balance of cda in the steady state. 27.3 μ M of cda are manufactured from tyrosine per hour. 81 μ M/hr of dopamine are put into the vesicles by the monoamine transporter and 80.1 μ M/hr are put back into the cytosol from the extracellular space by the DATs. Finally, 26.5 μ M/hr of dopamine is catabolized in the cytosol.
The largest portion of cellular dopamine is in the vesicles; in our model vda = 81 μ M at steady state. We assume that at a "normal" firing rate the vesicular contents would be emptied in an hour; that is, vda is released into the synaptic cleft at 81 μ M/hr. The DATs put most of this eda back into the cytosol (80.1 μ M/hr), with the remainder being removed (0.81 μ M/hr) or being catabolized (.02 μ M/hr). We will see below that these velocities are consistent with the half-life measurements of Caron and co-workers [24, 25].
A. Consequences of substrate inhibition of TH by tyrosine
Tyrosine hydroxylase (TH) converts the amino acid tyrosine into l-dopa and bh 4 into bh 2; l-dopa is then converted by aromatic amino acid decarboxylase into dopamine. Given the dynamic nature of neurons and the importance of dopamine, it is not surprising that TH is regulated by many different mechanisms. TH is inhibited by dopamine itself and is also inhibited by the D2 autoceptors that are stimulated by extracellular dopamine. The effects of these regulations will be discussed below. Here we focus on a third regulation, substrate inhibition of tyrosine hydroxylase by tyrosine . Substrate inhibition means that tyrosine can bind non-enzymatically to TH preventing TH from performing its function of converting tyrosine to l-dopa. Substrate inhibition can be competitive (one tyrosine binding to TH makes the catalytic site unavailable to another tyrosine) or uncompetitive (the catalytic site is available to another tyrosine but the enzyme does not perform its catalytic function). Substrate inhibition is not widely recognized as an important regulatory mechanism, though it was proposed by Haldane in the 1930s , and it known to have an important homeostatic function in the folate cycle . Figure 2 shows normal Michaelis-Menten kinetics, competitive substrate inhibition, and uncompetitive substrate inhibition. In uncompetitive substrate inhibition the velocity curves rises, reaches a maximum, and then descends to zero because at higher and higher tyrosine concentrations more and more enzyme is bound non-enzymatically to tyrosine.
The velocity curve, figure 2 of , shows clearly that the substrate inhibition of TH by tyrosine is uncompetitive and we have chosen our kinetic parameters to match the shape of that curve. The question that we wish to address here is what is the purpose of this substrate inhibition? We will see that it stabilizes vesicular dopamine in the face of variations in tyrosine availability.
To see the effect of substrate inhibition on the synthesis of L-Dopa by TH, we computed the time courses of the velocity of the TH reaction both with and without substrate inhibition, Panel B of Figure 3. Without substrate inhibition the velocity of the TH reaction varies from 23.5 to 28 μ M/hr while in the presence of substrate inhibition the variation ranges only from 27 to 28 μ M/hr.
This naturally raises the question of how much the levels of vesicular dopamine vary throughout the day in the two cases. Panel C of Figure 3 shows that substrate inhibition greatly reduces the variation.
We conclude that one important purpose of substrate inhibition is to stabilize the velocity of the TH reaction, and thus the vesicular stores of dopamine, in the face of large variations in tyrosine availability because of meals. The stabilization is a result of the relatively flat velocity curve in a large neighborhood (say 75 μ M to 175 μ M -see Figure 2) of the normal tyrosine concentration of 126 μ M. We note that the non-monotone shape of the velocity curve helps explain some of the unusual relationships between tyrosine levels and dopamine synthesis and release reported in the literature [73, 58, 56].
B. The response to prolonged stimulation
C. Dopamine turnover in tissues and extracellular space
Over the last 15 years Caron and co-workers have conducted numerous experiments with dominergic neurons. We focus here on the experiments reported in ,  and  that compare the behavior of extracellular dopamine and striatal tissue dopamine in wild type mice (WT) and mice that express no DATs at all (DAT-/-), the heterozygote (DAT+/-), and mice that overexpress the DATs (DAT-tg). The experiments of Caron and co-workers provide an exceptional opportunity to analyze the effects and importance of the DATs.
When we turn off the DATs in our model (by setting the V max to zero), we see changes in steady state values that are qualitatively similar to those seen in  and  but the magnitudes differ somewhat. The steady state value of eda rises by a factor of 10 in the model when the DATs are turned off, while it rises by only a factor of 5 in the DAT-/- mouse. In the model, vesicular dopamine declines from 81 μ M to 11 μ M when the DATs are turned off, while  and  report that striatal tissue dopamine in DAT-/- mice is only 1/20 of the value in WT. We modeled the heterozygote (DAT+/-) by reducing the V max of the DATs to 1/2 the normal value. The model eda increases by 50% compared to WT and vda declines by 27%, which is almost exactly the decline in striatal tissue DA reported in DAT+/- mice in (, figure 3). In general, one would not expect the model and experimental results to correspond exactly because the DAT-/- and DAT+/- mice have not had their DATs suddenly turned off as we are doing in the model. These mice have lived their whole lives with no or reduced DATs, respectively, so their dopaminergic neurons may differ in other ways from those of the WT mice.
We find in the model that the half-life of eda for WT mice is .067 seconds and the half-life for DAT-/- mice is approximately 6 seconds, giving a ratio of DAT-/- half-life to WT half-life of about 90. Caron and coworkers find similar numbers experimentally except that their ratio is about 300. We note that the ratio is sensitive, of course, to small changes in the small WT half-life that is determined both in experiments and in the model from a very steep curve.
D. The role of transporter kinetics in the regulation of extracellular dopamine
The first effect is that the amount of dopamine available to be released in response to an external pulse is not strictly proportional to the number of DATs. In the model "the number of DATs" is represented by the V max of the transporter. We increased the V max by 50% for DAT-tg mice compared to wild type, decrease it by 50% for DAT+/- mice, and decrease it to zero for DAT-/- mice. However, vda, the pool available for release, has the following model values: vda = 98.9 μ M (DAT-tg), vda = 81 μ M (WT), vda = 59 μ M (DAT+/-), vda = 11.4 μ M (DAT-/-). In the model, the amount of dopamine released in response to a pulse small enough not to deplete the vda pool very much is proportional to vda. Thus more dopamine is released in DAT-tg compared to WT compared to DAT+/- compared to DAT-/-. If this were the only effect then one would expect the eda peak to be highest for DAT-tg, lower for WT, still lower for DAT+/-, and lowest for DAT-/-.
The second effect is that if the cell has more DATs, then it should be able to pump the released eda back into the cell faster. Thus, if the amount released were the same in each case, we would expect the eda peak to be lowest for DATtg, somewhat higher for WT, still higher for DAT+/-, and highest for DAT-/-. However, as we have seen, the amount released is not the same but decreases as one progresses from DAT-tg to WT to DAT+/- to DAT-/-. These are the two competing effects that determine the heights of the peaks. The situation is even more complicated and interesting, however. The K m for the DAT has been measured in a number of experiments. A reasonable range of possible values is 0.2 μ M to 2 μ M; see  and . In the experiments in  and  the maximal eda concentrations were in the range 2-3 μ M. This means that if K m = 0.2 then the height of the peak will be highly affected by how much dopamine is released because the DATs are saturated.
In Panel B of Figure 7, we show the time courses of extracellular dopamine in model experiments where K m = 0.2 μ M. Notice that the peaks decrease as one goes from DATtg to WT to DAT+/- to DAT-/-. In each case the amount of stimulation was the same. This is what one would expect if the first effect, the amount of dopamine released, dominates. To test whether the saturation of the DATs causes this effect we did a model experiment in which the amount of stimulation was reduced to 1/10 of what it was before. The results can be seen in Panel C of Figure 7. At this lower stimulation level, the second effect dominates because the DATs are no longer saturated and the peaks increase as one goes from DAT-tg to WT to DAT+/-. Note also how much narrower the peaks are because the DATs are operating on the linear parts of their response curves rather than the saturation part. Panels B and C show that the peaks can be either decreasing or increasing as one proceeds from DAT-tg to WT to DAT+/-, depending only on the amount of stimulation. The DAT-/- peak remains lowest because it is not affected by saturation effects on the DATs, since there aren't any.
If we increase the K m of the DATs we will decrease the saturation effects seen in Panel B of Figure 7 and thus the two effects (amount released and rapidity of uptake) should be more evenly balanced. That is indeed the case as shown by Panel D of Figure 7. In Panel D the K m of the DATs has been raised to 1.6 μ M and everything else remains the same as in the model experiments shown in Panel B. Now the WT peak is higher than both the DAT-tg peak and the DAT+/- peak. The differences are not great, but the non-monotone effect is clear. As before, the DAT-/- peak is the lowest since so little dopamine is released.
These model experiments show that the relative heights of the peaks depend on the size of the vesicular stores, the number of DATs, their K m s, and the amount of stimulation.
E. The frequency of stimulation affects passive stabilization
where we take K m = 0.2 μ M as in our large model. For t > 2 the C isn't there any more but that doesn't affect the maximum concentration of E(t), which occurs at t = 2. We want to calculate E(2) and then introduce our scale factor f and see how the value scales with f.
The shape of the graph of E(2) as a function of f depends on the size of . Bergstrom and Garris measured a V max close to 4 μ M/sec and K m = 0.2 μ M, so ≈ 40. This means that the graph of E(2) will be almost constant as f gets smaller from 1. Only when f gets very very small will E(2) plunge down to zero. This is the constant behavior of the peaks seen in , figure 3(a), for 20 Hz stimulation.
Thus the maxima should decrease linearly with f and that's what Bergstrom and Garris see in their figure 3(b).
This calculation is correct as long as the concentration of E stays well above K m . The complete behavior as f goes from 1 to 0 in the 60 Hz case should be: first, this linear decrease, then a middle range around the K m value where the rate of decrease is more modest, then a flat plateau as in the first case we considered, until, finally, E(2) should plunge to 0 for almost complete denervation. As the ability to take accurate voltametric measurements improves, it will be interesting to see if this prediction is correct.
F. Homeostatic effects of the autoreceptors
Autoreceptors on the presynaptic membrane upregulate tyrosine hydroxylase(TH) when eda drops and downregulate TH when eda rises as it will do if the firing rate of the neuron increases [62, 61]. Thus, the autoreceptors provide a mechanism whereby the eda concentration provides feedback inhibition to TH. The strength of the effect can be seen in Panel B of Figure 9 where eda is graphed as a function of firing rate. The eda curve is much flatter in the presence of the autoreceptors. We note that the eda also affects firing rate directly via somatic autoreceptors , but this is not included in our model.
G. The effect of single action potentials and bursts
It is known [3, 4] that there are two typical firing patterns seen in the dopaminergic neurons of the SNc, tonic firing at about 5 Hz and bursts of action potentials with an intraburst frequency of about 15-30 Hz. Dopaminergic neurons respond to reward-related stimuli with increased burst firing [8, 79] and burst firing is more effective at raising dopamine levels than tonic firing [80, 45]. Recently bursts have been measured in awake, freely-moving animals [81, 47, 82] in response to rewards and in response to cues for the rewards when the cues have been learned; for a review, see .
The purpose of a mathematical model is not only to summarize or represent the biology that is already known, but to provide a platform for in silico experimentation that one can use to explain data, resolve controversies, and try out hypotheses. Our main focus in this paper is to help understand the many homeostatic mechanisms involved in dopamine synthesis, release and reuptake. We have demonstrated that substrate inhibition of tyrosine hydroxylase by tyrosine plays an important role in stabilizing vesicular dopamine against tyrosine fluctuations due to meals. In Section C we studied dopamine turnover and clearance from the extracellular space and compared model results to experimental data. In Section D we used the model to explain features of the time course of extracellualar dopamine observed by Caron and co-worers in DAT knockout and Dat-tg mice. In Section E we showed that the model reproduces the results of Bergstrom and Garris on the different responses to 20 Hz and 60 Hz stimulation and we provide an explanation. In Section F we showed that autoreceptors stabilize extracellular dopamine against changes in expression level of TH and modulate the influence of firing rate on extracellular dopamine concentration. Of course, the purpose of these homeostatic mechanisms is not to make the dopaminergic neuron a fixed object that always responds in the same way. On the contrary, the purpose of the homeostatic mechanisms is keep the neuron poised in the right state, despite environmental fluctuations, so that it can respond appropriately to significant biological signals. Thus, in Section G we showed that the tonic firing rate of 5 Hz keeps extracellular dopamine near normal, but an increase to only 15 Hz in a burst raises extracellular dopamine transiently but significantly. Thus, the neuron is able to send a dopaminergic signal with only a modest and transient increase in firing rate.
Any model includes many oversimplifications. We have not included the details of the use of tyrosine in other metabolic pathways. The processes by which vesicles are created, move to the synapse, and release their dopamine are complicated and interesting [84, 65], but are not included in this model. In our model the DATs put released dopamine back into the terminal, but we do not include leakage of cytosolic dopamine through the DATs into the extracellular space. We include in the model the effects of the autoreceptors on dopamine synthesis (via TH) but we do not include explicitly the effects of the autoreceptors on dopamine release and firing rate. Finally, we are focusing on the nerve terminal and on synaptic mechanisms and therefore do not include mechanisms, such as the effects of the autoreceptors on the dendrites and cell body, that operate at the level of the whole cell or between dopaminergic cells.
Such cellular and cell population effects are likely to play important roles in compensatory mechanisms in the case of dopaminergic cell loss. For example, extracellular dopamine concentrations in the striatum are maintained despite massive cell death in the substantia nigra [77, 46]. Both passive and active mechanisms including volume transmission, diffusion, and the autoreceptors play a role in this population effect, which we study in .
Understanding quantitatively the balance of different mechanisms in dopaminergic cells and cell populations may be crucial for determining proper therapeutic interventions for the dopaminergic dysfunctions mentioned in the introduction. This is a daunting task, complicated by the likelihood of multiple etiologies as well as interactions with nondopaminergic factors [85, 86]. Our future goal is to develop the mathematical model so we can use it to explore the variety of proposed hypotheses. We need to understand dopaminergic signaling in the cortex as well as in the basal ganglia in order to understand how the symptoms of Tourette's syndrome arise [87, 88]. Both Tourette's and Parkinson's disease press us to study the role of dopamine in shaping activity patterns in cortico-subcortico-cortical circuits and in particular the balance of activity among parallel circuits such as the direct and indirect pathways of the basal ganglia [85, 89]. Cognitive dysfunctions including Attention Deficit Hyperactivity Disorder have been attributed to such factors as altered dopamine synthesis  and to identified mutations altering the behavior of DATs. Modeling the effects of differential density of DATs  or vesicles  in dopaminergic neuron populations may help explain why, in the Parkinsonian process of dopaminergic neurodegeneration, neurons projecting to the striatum are characteristically affected earlier than those projecting to other areas such as the Nucleus Accumbens .
Dopaminergic systems must respond robustly to important biological signals such as bursts, while at the same time maintaining homeostasis in the face of normal biological fluctuations in inputs, expression levels, and firing rates. This is accomplished through the cooperative effect of many different homeostatic mechanisms including special properties of tyrosine hydroxylase, the dopamine transporters, and the dopamine autoreceptors. Understanding quantitatively the effects of these homeostatic mechanisms in normal and pathological situations is crucial for the design of therapeutic strategies in a number of neurodegenerative diseases and neuropsychiatric disorders.
The authors thank Marc Caron and Raul Gainetdinov for helpful discussions. This work was supported by NSF grant DMS-061670 (MR, HFN), NSF agreement 0112050 through the Mathematical Biosciences Institute (JB, MR), AFOSR grant FA9550-06-1-0033 (JB) and NIH grant RO1 CA105437 (MR, HFN).
- Dichiara G, Bassareo V, Fenu S, Luca MD, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D: Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacol. 2004, 47: 227-241. 10.1016/j.neuropharm.2004.06.032.Google Scholar
- Kuchel O, Kuchel G: Peripheral dopamine in pathophysiology of hypertension. Interaction with aging and lifestyle. Hypertension. 1991, 18: 709-721.PubMedGoogle Scholar
- Feldman R, Meyer J, Quenzer L: Principles of Neuropharmacology. 1997, Sunderland, MA.: Sinauer Associates, IncGoogle Scholar
- Cooper J, Bloom F, Roth R: The Biochemical Basis of Neuropharmacology. 2003, New York, NY: Oxford U. PressGoogle Scholar
- Halbach OBU, Dermietzel R: Neurotransmitters and Neuromodulators, Handbook of Receptors and Biological Effects. 2002, Weinheim: Wiley BCH-VerlagGoogle Scholar
- Dzirasa K, Ribiero S, Costa R, Santos L, Lin S, Grossmark A, Sotnikova T, Gainet-dinov R, Caron M, Nicolelis M: Dopaminergic control of sleep-wake states. J Neurosci. 2006, 26: 10577-10589. 10.1523/JNEUROSCI.1767-06.2006.PubMedGoogle Scholar
- Wise R: Dopamine, learning and motivation. Nature Rev Neurosci. 2004, 5: 1-12.Google Scholar
- Schultz W: Multiple reward signals in the brain. Nat Rev Neurosci. 2000, 1: 199-207. 10.1038/35044563.PubMedGoogle Scholar
- Graybiel A, Flaherty TA, Kimura M: The basal ganglia in adaptive motor control. Science. 1994, 265: 1826-1831. 10.1126/science.8091209.PubMedGoogle Scholar
- DeLong M: Primate models of movement disorders of basal ganglia origin. TINS. 1990, 13: 281-285.PubMedGoogle Scholar
- Nieoullon A: Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002, 571: 1-31.Google Scholar
- Jay T: Dopamine: a potential substrate for synaptic plasticity in memory mechanisms. Prog Neurobiol. 2003, 69: 375-390. 10.1016/S0301-0082(03)00085-6.PubMedGoogle Scholar
- Arbuthnott G, Ingham C, Wickens J: Dopamine and synaptic plasticity in the neostriatum. J Anatomy. 2000, 196: 587-596. 10.1046/j.1469-7580.2000.19640587.x.Google Scholar
- Yao WD, Gainetdinov R, Arbuckle M, Sotnikova T, Cyr M, Beaulieu JM, Torres G, Grant S, Caron M: Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron. 2004, 41: 625-638. 10.1016/S0896-6273(04)00048-0.PubMedGoogle Scholar
- Kienast T, Heinz A: Dopamine in the diseased brain. CNS Neuro Disord - Drug Targ. 2006, 5: 109-131. 10.2174/187152706784111560.Google Scholar
- Lotharius J, Brundin P: Pathogenisis of Parkinson's disease: dopamine vesicles and α-synuclein. Nature Rev Neurosci. 2002, 3: 932-942. 10.1038/nrn983.Google Scholar
- Jankovic J: Tourette's syndrome. N Engl J Med. 2001, 345: 1184-1192. 10.1056/NEJMra010032.PubMedGoogle Scholar
- Heaton J: Central neural pharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev. 2000, 24: 561-569. 10.1016/S0149-7634(00)00023-3.PubMedGoogle Scholar
- Gainetenov R, Jones S, Fumagalli F, Wightman R, Caron M: Reevaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Rev. 1998, 26: 148-153. 10.1016/S0165-0173(97)00063-5.Google Scholar
- Roth R, Elworth J: Biochemical pharmacology of midbrain dopamine neurons. Psychopharmacology: The Fourth Generation of Progress. 1995, Raven, New York, 227-243.Google Scholar
- Palop J, Chin J, Mucke L: A Network dysfunction perspective on neurodegenerative diseases. Nature. 2006, 443: 769-773. 10.1038/nature05289.Google Scholar
- Reed M, Best J, Nijhout H: Passive and active stabilization of dopamine in the striatum. BioScience Hypotheses. 2009, 2: 240-244. 10.1016/j.bihy.2009.03.008.Google Scholar
- Nakashima A, Mori K, Suzuki T, Kurita H, Otani M, Nagatsu T, Ota A: Dopamine inhibition of human tyrosine hydroxylase type I is controlled by the specific portion of the N-terminus of the enzyme. J Neurchem. 1999, 72: 2145-2153. 10.1046/j.1471-4159.1999.0722145.x.Google Scholar
- Jones S, Gainetdinov R, Jaber M, Giros B, Wightman R, Caron M: Profound neuronal plasticity in response to inactivation of the dopamine trasporter. PNAS. 1998, 95: 4029-4034. 10.1073/pnas.95.7.4029.PubMed CentralPubMedGoogle Scholar
- Sotnikova T, Beaulieu JM, Barak L, Wetsel W, Caron M, Gainetdinov R: Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of parkinson disease. PLOS Biology. 2005, 3: 1488-1500. 10.1371/journal.pbio.0030271.Google Scholar
- Kehr W, Lindqvist ACM, Magnusson , Atack C: Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol. 1972, 24: 744-746.PubMedGoogle Scholar
- Walters J, Roth R: Dopaminergic neurons: drug-induced antagonism of the increase in tyrosine hydroxylase activity produced by cessation of impulse flow. J Pharmacol Exp Ther. 1974, 191: 82-91.PubMedGoogle Scholar
- Alter C, Boyer W, Oei E, Wood P: Dopamine Autoreceptors Modulate the in Vivo Release of Dopamine in the Frontal, Cingulate and Entorhinal Cortices. J Pharmacol Exper Therap. 1987, 242: 115-120.Google Scholar
- Pothos E, Przedborski S, Davila V, Schmitz Y, Sulzer D: D2-Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells. J Neurosci. 1998, 18: 5575-5585.PubMedGoogle Scholar
- Urban J, Vargas G, von Zastrow M, Mailman R: Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways. Neuropsychopharm. 2007, 32: 67-77. 10.1038/sj.npp.1301071.Google Scholar
- Tissari A, Lillgals M: Reduction of dopamine synthesis inhibition by dopamine autoreceptor activation in striatal synaptosomes with in vivo resperine administration. J Neurochem. 1993, 61: 231-238. 10.1111/j.1471-4159.1993.tb03559.x.PubMedGoogle Scholar
- Jones S, Gainetdinov R, Hu XT, Cooper D, Wightman R, Caron M: Loss of autoreceptor functions in mice lacking the dopamine transporter. Nature Neurosci. 1999, 2: 649-655. 10.1038/10204.PubMedGoogle Scholar
- Justice J, Nicolaysen L, Michael A: Modeling the dopaminergic nerve terminal. J Neurosci Meth. 1988, 22: 239-252. 10.1016/0165-0270(88)90045-3.Google Scholar
- Michael A, Ikeda M, Justice J: Mechanisms contributing to the recovery of striatal releasable dopamine following MFB stimulation. Brain Res. 1987, 421: 325-335. 10.1016/0006-8993(87)91302-3.PubMedGoogle Scholar
- Michael A, Ikeda M, Justice J: Dynamics of the recovery of releasable dopamine following electrical stimulation of the medial forebrain bundle. Neurosci Lett. 1987, 76: 81-86. 10.1016/0304-3940(87)90196-0.PubMedGoogle Scholar
- Church W, Justice J, Byrd L: Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol. 1987, 139: 345-348. 10.1016/0014-2999(87)90592-9.PubMedGoogle Scholar
- Porenta G, Riederer P: A mathematical model of the dopaminergic synapse: stability and sensitivity analyses, and simulation of Parkinson's disease. Cyber Syst. 1982, 13: 257-274. 10.1080/01969728208927705.Google Scholar
- Tretter F, Eberle E, Scherer J: A basic mathematical model of a dopamine synapse. Cyber Syst. 2002, 1: 335-339.Google Scholar
- Nicholson C: Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys J. 1995, 68: 1699-1715. 10.1016/S0006-3495(95)80348-6.PubMed CentralPubMedGoogle Scholar
- Qi Z, Miller G, Voit E: Computational systems analysis of dopamine metabolism. PLoS ONE. 2008, 3: 1-10.Google Scholar
- Qi Z, Miller G, Voit E: A mathematical model of presynaptic dopamine homeostasis: implications for schizophrenia. Pharmacopsychiatry. 2008, 41: S89-S98. 10.1055/s-2008-1080936.PubMedGoogle Scholar
- Kaushik P, Gorin F, Vali S: Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. J Comp Neurosci. 2007, 22: 147-160. 10.1007/s10827-006-0004-8.Google Scholar
- de la Fuente-Fernandez R, Schulzer M, Mak E, Caine D, Stoessl A: Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain. 2004, 127: 888-899. 10.1093/brain/awh102.PubMedGoogle Scholar
- Wightman R, Amatore C, Engstrom R, Hale P, Kristensen E, Kuhr W, May L: Real-time characterization of dopamine overflow and uptake in the rat striatum. Neurosci. 1988, 25: 513-523. 10.1016/0306-4522(88)90255-2.Google Scholar
- Garris P, Wightman R: Different kinetics govern dopaminergic neurotransmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltametric study. J Neurosci. 1994, 14: 442-450.PubMedGoogle Scholar
- Bergstrom B, Garris P: 'Passive stabilization' of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltametric study in the 6-OHDA-lesioned rat. J Neurochem. 2003, 87: 1224-36. 10.1046/j.1471-4159.2003.02104.x.PubMedGoogle Scholar
- Montague P, McClure S, Baldwin P, Phillips P, Budygin E, Stuber G, Kilpatrick M, Wightman R: Dynamic gain control of dopamine delivery in freely moving animals. J Neurosci. 2004, 24: 1754-1759. 10.1523/JNEUROSCI.4279-03.2004.PubMedGoogle Scholar
- Venton B, Zhang H, Garris P, Sulzer D, Phillips P, Wightman R: Real-time decoding of dopamine neurotransmission in the caudate-putamen during tonic and phasic firing. J Neurochem. 2003, 87: 1284-1295. 10.1046/j.1471-4159.2003.02109.x.PubMedGoogle Scholar
- Dickinson J, Rosenblum H, Hamilton P: Ion exchange chromatography of the free amino acids in the plasma of the newborn infant. Pediatrics. 1965, 36: 2-13.PubMedGoogle Scholar
- Long C, (Ed): Biochemists' Handbook. 1961, Princeton, NJ: Van NostrandGoogle Scholar
- Kilberg M, Haussinger D: Mammalian Amino Acid Transport, Mechanisms and Control. 1992, New York: Plenum PrGoogle Scholar
- Michal G: Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology. 1999, New York: WileyGoogle Scholar
- Mains R, Patterson P: Primary cultures of dissociated sympathetic neurons. II. Initial studies on catecholamine metabolism. J Cell Biol. 1973, 59: 346-360. 10.1083/jcb.59.2.346.PubMed CentralPubMedGoogle Scholar
- Coenen H, Kling P, Stocklin G: Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med. 1989, 30: 1367-1372.PubMedGoogle Scholar
- Cumming P, Asa A, Kuwabara H, Gjedde A: [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis. J Cereb Blood Flow Metab. 1998, 18: 491-499. 10.1097/00004647-199805000-00004.PubMedGoogle Scholar
- Bongiovanni R, Young D, Newbould E, Jaskiw E: Increased striatal dopamine synthesis is associated with decreased tissue levels of tyrosine. Brain Res. 2006, 1115: 26-36. 10.1016/j.brainres.2006.07.074.PubMedGoogle Scholar
- Fernstrom J, Fernstrom M: Dietary effects on tyrosine availability and cat-acholamine synthesis in the central nervous system: possible relevance to the control of protein intake. Proc Nutr Soc. 1994, 53: 419-429. 10.1079/PNS19940047.PubMedGoogle Scholar
- Bongiovanni R, Kirkbride B, Walmire P, Jaskiw E: Tyrosine administration does not affect desipromine-induced dopamine levels as measured in vivo in prefrontal cortex. Brain Res. 2005, 1054: 203-206. 10.1016/j.brainres.2005.06.070.PubMedGoogle Scholar
- Ribiero P, Wang Y, BA BC, Kaufman S: Regulation of recombinant rat ty-rosine hydroxylase by dopamine. PNAS. 1992, 89: 9593-9597. 10.1073/pnas.89.20.9593.Google Scholar
- Royo M, Daubner S, Fitzpatrick P: Effects of mutations in tyrosine hydroxylase associated with progressive dystonia on the activity and stability of the protein. Proteins. 2004, 58: 14-21. 10.1002/prot.20293.Google Scholar
- Benoit-Marand M, Borrelli E, Gonon F: Inhibition of Dopamine Release Via Presynaptic D2 Receptors: Time Course and Functional Characteristics In Vivo. J Neurosci. 2001, 21: 9134-9141.PubMedGoogle Scholar
- Koeltzow T, Xu M, Cooper D, Hu XT, Tonegawa S, Wolf M, White F: Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci. 1998, 18: 2231-2238.PubMedGoogle Scholar
- Glowinski SMJ, Hamon M: Presynaptic Dopamine Autoreceptors Control Tyrosine Hydroxylase Activation in Depolarized Striatal Dopaminergic Terminals. J Neurochem. 1986, 46: 12-22. 10.1111/j.1471-4159.1986.tb12919.x.PubMedGoogle Scholar
- Missale C, Nash S, Robinson S, Jaber M, Caron M: Dopamine Receptors: From Structure to Function. Physiol Rev. 1998, 78: 189-225.PubMedGoogle Scholar
- Floor E, Leventhal P, Wang Y, Meng L, Chen W: Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem. 1995, 64: 689-699.PubMedGoogle Scholar
- Wallace L: A small dopamine permeability of storage vesicles membranes and end product inhibition of tyrosine hydroxylase are sufficient to explain changes occurring in dopamine synthesis and storage after inhibition of neuronal firing. Synapse. 2007, 61: 715-723. 10.1002/syn.20408.PubMedGoogle Scholar
- O'Carroll A, Fowler C, Phillips J, Tipton ITK: The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Arch Pharmacol. 1983, 322: 198-202. 10.1007/BF00500765.Google Scholar
- Rivett A, Roth J: Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Biochem. 1982, 21: 1740-1742. 10.1021/bi00537a006.Google Scholar
- Karoum F, Norton H, Wyatt R: The dynamics of dopamine metabolism in various regions of rat brain. Eur J Pharmacol. 1977, 44: 311-318. 10.1016/0014-2999(77)90304-1.PubMedGoogle Scholar
- Dedek J, Baumes R, Tien-Duc N, Gomeni R, Korf J: Turnover of free and conjugated (sulphonyloxy) dihydrophenylacetic acid and homovanillic acid in rat striatum. J Neurochem. 1979, 33: 687-695. 10.1111/j.1471-4159.1979.tb05213.x.PubMedGoogle Scholar
- Haldane J: Enzymes. 1930, New York: Longmans, Green and CoGoogle Scholar
- Nijhout H, Reed M, Budu P, Ulrich C: A mathematical model of the folate cycle: New insights into folate homeostasis. J Biol Chem. 2004, 279: 55008-55016. 10.1074/jbc.M410818200.PubMedGoogle Scholar
- Melamed E, Hefti F, Wurtman R: Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. PNAS. 1980, 77: 4305-4309. 10.1073/pnas.77.7.4305.PubMed CentralPubMedGoogle Scholar
- Salahpour A, Ramsey A, Medvedev I, Kile B, Sotnikova T, Holmstrand E, Ghisi V, Nicholls P, Wong L, Murphy K, Sesack S, Wightman R, Gainetdinov R, Caron M: Increased amphetamine-induced hyperactivity and reward in mice overexpresing the dopamine transporter. PNAS. 2008, 105: 4405-4410. 10.1073/pnas.0707646105.PubMed CentralPubMedGoogle Scholar
- Jones S, Garris P, Kilts C, Wightman R: Comparison of dopamine uptake in the basolateral amygdaloid nucleaus, caudate-putamen, and nucleus accumbems of the rat. J Neurochem. 1995, 64: 2581-2589.PubMedGoogle Scholar
- Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D: Presynaptic regulation of dopaminergic neurotransmission. J Neurochem. 2003, 87: 273-289. 10.1046/j.1471-4159.2003.02050.x.PubMedGoogle Scholar
- Garris P, Walker Q, Wightman R: Dopamine release and uptake both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res. 1997, 753: 225-234. 10.1016/S0006-8993(97)00003-6.PubMedGoogle Scholar
- Sigal A, Milo R, Cohen A, Geva-Zatorsky N, Klein Y, Liron Y, Rosenfeld N, Danon T, Perzov N, Alon U: Variability and memory of protein levels in human cells. Nature. 2006, 444: 643-646. 10.1038/nature05316.PubMedGoogle Scholar
- Reynolds BHJ, Perk JHC, Miller R: Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience. 2002, 114: 475-492. 10.1016/S0306-4522(02)00267-1.PubMedGoogle Scholar
- Gonon F, Buda M: Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltametry in the rat striatum. Neuroscience. 1985, 14: 765-774. 10.1016/0306-4522(85)90141-1.PubMedGoogle Scholar
- Robinson D, Venton J, Heien M, Wightman R: Detecting subsecond dopamine release with fast-scan cyclic voltametry in vivo. Clinical Chemistry. 2003, 49: 1763-1773. 10.1373/49.10.1763.PubMedGoogle Scholar
- Heien M, Wightman R: Phasic dopamine signaling during behavior, reward, and disease states. CNS Neuro Disord - Drug Targ. 2006, 5: 99-108. 10.2174/187152706784111605.Google Scholar
- Venton B, Wightman R: Psychoanalytical electrochemistry: dopamine and behavior. Anal Chem. 2003, 75: 414A-421A. 10.1021/ac031421c.Google Scholar
- Reimer R, Fon E, Edwards R: Vesicular neurotransmitter transport and the presynaptic regulation of quantal size. Curr Opin Neurobiol. 1998, 8: 405-412. 10.1016/S0959-4388(98)80068-8.PubMedGoogle Scholar
- Leckman J, Peterson B, Anderson G, Arnsten A, Pauls D, Cohen D: Pathogenesis of Tourette's Syndrome. J Child Psychol Psychiat. 1997, 38: 119-142. 10.1111/j.1469-7610.1997.tb01508.x.PubMedGoogle Scholar
- Sawa A, Snyder S: Schizophrenia: diverse approaches to a complex disease. Science. 2002, 296: 692-695. 10.1126/science.1070532.PubMedGoogle Scholar
- Leckman J: Tourette's Syndrome. The Lancet. 2002, 360: 1577-1586. 10.1016/S0140-6736(02)11526-1.Google Scholar
- Comings D: A controlled study of Tourette's sundrome. VII. Summary: A common genetic disorder causing disinhibition of the limbic system. Am J Hum Genet. 1987, 41: 839-866.PubMed CentralPubMedGoogle Scholar
- Smith Y, Bevan M, Bolam J: Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 1998, 86: 353-387. 10.1016/S0306-4522(97)00608-8.PubMedGoogle Scholar
- Forssberg H, Fernell E, Waters S, Waters N, Tedroff J: Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. Behavioral and Brain Functions. 2006, 2: 40-10.1186/1744-9081-2-40.PubMed CentralPubMedGoogle Scholar
- Hahn M, Blakely R: Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenom J. 2002, 2: 217-235. 10.1038/sj.tpj.6500106.Google Scholar
- Nirenberg M, Chan J, Pohorille A, Vaughan R, Uhl G, Kuhar M, Pickel V: The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. The J Neurosci. 1997, 17: 6899-6907.PubMedGoogle Scholar
- Miller G, Gainetdinov R, Levey A, Caron M: Dopamine transporters and neuronal injury. Trends in Pharmacological Sciences. 1999, 20: 424-429. 10.1016/S0165-6147(99)01379-6.PubMedGoogle Scholar
- Siaterli M, Vassilacopoulou D, Fragoulis E: Cloning and expression of human placental L-Dopa decarboxylase. Neurochem Res. 2003, 28: 797-803. 10.1023/A:1023246620276.PubMedGoogle Scholar
- Armarego W, Ohnishi A, Taguchi H: New pteridine substrates for dihydropteridine reductase and horseradish peroxidase. Biochem J. 1986, 234: 335-342.PubMed CentralPubMedGoogle Scholar
- Bailey S, Ayling J: 6,6-Dimethylpterins: stable quinoid dihydropterin substrate for dihydropteridine reductase and tetrahydropterin cofactor for phenylalanine hydroxylase. Biochem. 1983, 22: 1790-1798. 10.1021/bi00277a008.Google Scholar
- Firgaira F, Cotton R, Jennings I, Danks D: Use of naphthoquinone adsorbant for the isolation of human dihydropteridine reductase. Meth Enzymol. 1987, 142: 116-126. full_text.PubMedGoogle Scholar
- Firgaira F, Cotton R, Danks D: Isolation and characterization of dihydropteridine reductase from human liver. Biochem J. 1981, 97: 31-43.Google Scholar
- Schomburg D, Schomburg I: 6,7-Dihydropteridine Reductase. Springer Handbook of Enzymes. 2005, 23: 248-272. full_text.Google Scholar
- Craine J, Hall E, Kaufman S: The isolation and characterization of dihydropteridine reductase from sheep liver. J Biol Chem. 1972, 247: 6082-6091.PubMedGoogle Scholar
- Sherman D, Henry J: The catecholamine carrier of bovine chromaffin granules. Molec Pharamacol. 1983, 23: 431-436.Google Scholar
- Near J: [3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol Pharmacol. 1986, 30: 252-257.PubMedGoogle Scholar
- Volz T, Hanson G, Fleckenstein A: Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse. 2006, 60: 474-477. 10.1002/syn.20321.PubMedGoogle Scholar
- Morgenroth V, Walters J, Roth R: Dopaminergic neurons - alteration in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow. Biochemical Pharacology. 1976, 25: 655-661. 10.1016/0006-2952(76)90240-9.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.